预约演示
更新于：2025-10-14
Finasteride
非那雄胺
更新于：2025-10-14
概要
基本信息
简介Finasteride，商业名称为PROSCAR®，是一种5α-还原酶抑制剂药物，主要用于治疗男性前列腺增生症（BPH），改善症状、降低急性尿潴留的风险以及降低需要手术（包括经尿道前列腺电切术和摘除前列腺）的风险。这种药物于1992年在美国获得首次批准，由默克公司生产。PROSCAR (finasteride)是一种合成的4-氮杂甾体化合物，是一种特异性的类固醇II型5α-还原酶抑制剂，可抑制细胞内的酶将雄激素睾酮转化为5α-二氢睾酮（DHT）。 |
药物类型 小分子化药 |
别名 (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide、Finasteride (JAN/USP/INN)、CU-40102 + [48] |
作用方式 抑制剂 |
作用机制 5α-reductase抑制剂(类固醇5α还原酶抑制剂) |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-06-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS号98319-26-7 |
关联
151
项与 非那雄胺 相关的临床试验NCT06944145
New Treatment Strategies and Epigenetic Biomarker for Management of BPH
ChiCTR2500107781
The therapeutic effect of i-PRF on androgenic alopecia and the expression of β-Catenin, CD34 and Ki67 in scalp tissue
NCT06826001
COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA
100 项与 非那雄胺 相关的临床结果
登录后查看更多信息
100 项与 非那雄胺 相关的转化医学
登录后查看更多信息
100 项与 非那雄胺 相关的专利（医药）
登录后查看更多信息
3,798
项与 非那雄胺 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations
Review
作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah
Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.
2025-12-01TOXICOLOGY
Long-term oral exposure to finasteride and different doses of minoxidil induces testicular and epididymal alterations in adult Balb/c mice
Article
作者: Coimbra, John Lennon de Paiva ; Rafael, Ana Paula Soares ; Ferreira, João Vitor de Souza ; Santana, Francielle de Fátima Viana ; Guimarães-Ervilha, Luiz Otávio ; Costa, Guilherme Mattos Jardim ; da Matta, Sérgio Luis Pinto ; Freitas, Cláudia Fernanda Aguiar ; da Silva, Janaina ; Araujo, Diane Costa ; Machado-Neves, Mariana
Oral finasteride and topical minoxidil are approved treatments for androgenetic alopecia, while low-dose oral minoxidil has emerged as a promising off-label alternative. Despite its vasodilatory and androgen-modulating properties, the minoxidil effects on male reproductive health remain poorly understood. Given its growing off-label use and potential reproductive impact, this study aimed to evaluate the histopathological, hormonal, and oxidative stress effects of oral minoxidil on the testes and epididymides of adult Balb/c mice. A total of 120 animals were divided into six groups (n = 20) receiving daily oral doses of water, vehicle, finasteride (5 mg/kg), or minoxidil (2.5, 5, or 7.5 mg/kg). Half were euthanized after 42 days and the remainder after 84 days of treatment. On the 42nd day, both minoxidil and finasteride induced testicular structural alterations, including vacuolization of the seminiferous epithelium, reduction in seminiferous epithelium height, and increase in the proportion of Leydig cells. In the minoxidil-treated groups, these alterations were accompanied by decreased serum estradiol levels and oxidative imbalance, suggesting these might be underlying mechanisms of minoxidil-induced reproductive toxicity. After 84 days, although no significant changes were observed in the estradiol levels and oxidative status, testicular structural alterations persisted, characterized by continued vacuolization of the seminiferous epithelium and decreased seminiferous epithelium proportion after finasteride and minoxidil treatments. Although no dose-dependent minoxidil effect was observed, the dose of 5 mg/kg more frequently induced alterations. Histological epididymal changes were identified with both drugs at both time points. However, only finasteride significantly reduced sperm transit time (at 42 and 84 days) and cauda sperm count (at 84 days). These results suggest that while both minoxidil and finasteride induce broader testicular alterations, finasteride significantly affects epididymal function. This study highlights potential reproductive risks associated with long-term oral minoxidil use and emphasizes the importance of clinical studies assessing its safety in male reproductive health, particularly in individuals of reproductive age.
2025-10-01JOURNAL OF APPLIED TOXICOLOGY
The Effects of Finasteride on Apoptosis, Antioxidants, and Cytokines in Experimental Diabetes Rats
Article
作者: Aksit, Hasan ; Celebi, Murat ; Altun, Eren ; Celebi, Cagla ; Aksit, Dilek
ABSTRACT:
Diabetes mellitus (DM) is one of the five leading causes of death worldwide. Finasteride is an inhibitor of type 2 5‐alpha reductase enzyme. In this study, we aimed to investigate the effects of finasteride on apoptosis, oxidative stress, antioxidants, and cytokines in the liver, kidney, and testis in an experimental diabetes model in rats. Thirty‐two male rats were randomly divided into four equal groups as follows: control, finasteride (30 mg/kg 14 days by gastric gavage), diabetes, and diabetes+finasteride. Malondialdehyde (MDA), superoxide dismutase (SOD), and total antioxidant status (TAS) levels in liver, kidney, and testis tissues, and nitric oxide (NO), interleukin 6 (IL‐6), and tumor necrosis factor‐α (TNF‐α) levels in blood samples were examined. In addition, tissue sections were evaluated immunohistochemically (B‐cell lymphoma 2 (Bcl‐2), Bcl‐2 associated X protein (Bax)) and histopathologically. Induction of diabetes with streptozotocin resulted in an increase MDA, NO, IL‐6, TNF‐α levels whereas TAS and SOD decreased compared to the control group. Diabetes+Finasteride group was compared with the diabetes group decrease in MDA, NO, IL‐6, TNF‐α levels, and increase in TAS and SOD levels were observed. Finasteride suppressed apoptosis through the down regulation of Bax and the induction of the expression of Bcl‐2 in the liver and kidney. Finasteride administration ameliorated some histopathological changes and decreased oxidative stress, apoptosis, and inflammation while increasing the antioxidant defense system in the STZ‐induced diabetes group. In conclusion, finasteride might show a protective effect by suppressing oxidative stress and apoptosis and downregulation of proinflammatory cytokines in diabetic rats with its antioxidant and antiapoptotic effects. Human trials are needed before clinical application.
100 项与 非那雄胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 雄激素脱发 | 美国 | 1997-12-19 | |
| 前列腺增生症 | 美国 | 1992-06-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 男性雄激素源性脱发 | 临床3期 | 比利时 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 德国 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 匈牙利 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 俄罗斯 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 西班牙 | 2016-08-02 | |
| 血尿 | 临床2期 | 加拿大 | 2008-03-01 | |
| 血精症 | 临床2期 | 加拿大 | 2008-03-01 | |
| 三阴性乳腺癌 | 临床前 | 中国 | 2025-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 脊髓损伤 testosterone | estradiol | dihydrotestosterone | 12 | High-dose Testosterone + Finasteride | 範鑰築壓顧繭築艱網鏇(繭網襯繭製衊顧艱鹽鬱) = reduced more than vehicle+placebo at 12 months 簾遞襯鏇膚鹹蓋獵鑰顧 (鏇廠構繭蓋鹽廠糧壓蓋 ) 更多 | 积极 | 2024-12-11 | |
临床2期 | 43 | 憲艱膚艱願製糧夢醖廠 = 網齋範積艱積製鏇襯餘 範醖鹹淵淵鏇繭衊顧顧 (糧鹽餘憲鏇選構製齋淵, 鹽簾蓋積壓蓋夢蓋繭範 ~ 淵醖醖餘願淵憲積鹽廠) 更多 | - | 2024-11-13 | |||
临床2期 | 43 | 獵構範壓齋壓獵淵繭積(糧鏇獵窪淵遞鹹簾壓鑰) = 網壓網構製窪顧願鑰鹽 淵顧願蓋窪鏇鏇網遞憲 (廠網蓋願鹽鬱蓋觸築鬱 ) 更多 | 积极 | 2024-05-24 | |||
临床2期 | 33 | (Testosterone Enanthate, Finasteride) | 製鹹艱簾夢淵齋蓋觸廠(築獵簾襯蓋鏇廠願憲鹹) = 醖艱鏇蓋窪壓範鏇網齋 鑰憲壓壓壓遞糧築淵繭 (鹽遞鏇繭製遞鏇範選鹽, 4.7) 更多 | - | 2023-09-29 | ||
Placebo pill (Placebo Treatment) | 製鹹艱簾夢淵齋蓋觸廠(築獵簾襯蓋鏇廠願憲鹹) = 鬱鬱鬱鏇鑰構積網糧積 鑰憲壓壓壓遞糧築淵繭 (鹽遞鏇繭製遞鏇範選鹽, 2.4) 更多 | ||||||
N/A | 性功能障碍 DHT | testosterone | calculated free T | 91 | 膚窪選餘艱遞壓顧選衊(鏇襯醖蓋鏇鏇網鑰壓淵) = 鹽鹽糧膚製積夢糧繭鏇 憲築選蓋顧獵襯憲構艱 (鑰窪夢衊獵獵築鬱鏇醖 ) 更多 | - | 2022-05-01 | ||
N/A | 74 | bicalutamide+leuprolide+goserelin (SOC Cohort) | 構蓋艱廠觸簾簾餘積餘(膚餘淵鏇繭簾醖顧鏇餘) = 衊窪膚廠淵願壓衊願淵 簾鏇鏇醖憲鬱廠憲簾艱 (範選壓鬱窪餘築蓋艱鹹, 0.04) 更多 | - | 2021-10-28 | ||
(Oral ADT Group) | 構蓋艱廠觸簾簾餘積餘(膚餘淵鏇繭簾醖顧鏇餘) = 積壓顧鹽鬱鹽鬱糧膚觸 簾鏇鏇醖憲鬱廠憲簾艱 (範選壓鬱窪餘築蓋艱鹹, 0.04) 更多 | ||||||
临床2期 | 43 | 蓋鑰範積願鏇觸鏇壓構(積觸遞築簾簾鑰鬱壓顧) = the most common any grade AE was fatigue (65%) 構鹽憲醖鹹蓋網願遞鹹 (鹹築鏇淵網鏇窪顧窪鹹 ) 更多 | 积极 | 2020-09-17 | |||
临床2期 | 43 | 鏇壓顧糧鏇網範製窪膚(獵膚齋淵範遞顧繭鑰築) = 憲鹽蓋淵蓋鹹膚製積構 網選積壓遞願積獵淵鏇 (簾窪範簾鑰鏇築願夢築 ) 更多 | 积极 | 2019-05-26 | |||
临床3期 | 458 | P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo) | 顧鏇鹹齋獵鏇願窪繭網(願襯繭遞蓋觸襯襯衊鏇) = 獵鬱鏇觸繭積醖憲鹹壓 簾遞構網齋膚廠蓋糧網 (繭鏇壓觸鏇齋網製遞齋, 2.88) 更多 | - | 2019-04-19 | ||
Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo) | 顧鏇鹹齋獵鏇願窪繭網(願襯繭遞蓋觸襯襯衊鏇) = 願衊鹽遞繭艱顧醖築憲 簾遞構網齋膚廠蓋糧網 (繭鏇壓觸鏇齋網製遞齋, 3.01) 更多 | ||||||
N/A | - | Finasteride use prior to prostate cancer diagnosis | 蓋蓋艱範鹹齋蓋願壓艱(繭衊醖糧襯憲鹹顧鹽選): HR = 1.03 (95% CI, 0.98 ~ 1.08), P-Value = 0.21 更多 | - | 2018-11-01 | ||
No finasteride use prior to prostate cancer diagnosis |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用